Tag results:

ovarian cancer

Three Researchers Honoured for Groundbreaking Work on Ovarian Cancer, Stem Cells and Blood Transfusions

[Ottawa Citizen] Each year, the Ottawa Hospital honours three outstanding researchers for discoveries that are having an impact around the world. This year’s honourees have led game-changing discoveries and clinical trials in areas such as ovarian cancer, stem cells and blood transfusions.

Mesenchymal Stem Cell Therapy in Decompensated Liver Cirrhosis: A Long-Term Follow-Up Analysis of the Randomized Controlled Clinical Trial

[Hepatology International] Therapy of umbilical cord-derived MSC was not only well tolerated, but also significantly improved long-term survival rate, as well as the liver function in patients with Hepatits B Virus-related decompensated liver cirrhosis.

B7-H3 Suppresses Anti-Tumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

[Cancer Immunology Research] Transcriptome analysis revealed that B7-H3 was highly expressed in PD-L1-low, non-immunoreactive high-grade serous ovarian cancer tumors, and its expression negatively correlated with an IFNγ signature, which reflected the tumor immune-reactivity.

Oncolytic Adenovirus Inhibits Malignant Ascites of Advanced Ovarian Cancer via Reprograming Ascitic Immune Microenvironment

[Molecular Therapy-Oncolytics] Scientists found that oncolytic adenovirus conferred an effective ability to reduce ascites development and prolong overall survival.

Cancer-Associated MSC Drive Tumor Immune Exclusion and Resistance to Immunotherapy, Which Can Be Overcome by Hedgehog Inhibition

[Science Advances] Using an immune “hot” mouse ovarian cancer model, scientists found that cancer-associated-MSCs drove CD8+ T cell tumor immune exclusion and reduced response to anti–PD-L1 immune checkpoint inhibitor via secretion of numerous chemokines.

TCP1 Increases Drug Resistance in Acute Myeloid Leukemia by Suppressing Autophagy via Activating AKT/mTOR Signaling

[Cell Death & Disease] Scientists discovered that the T-complex protein 1 (TCP1) expression was elevated in acute myeloid leukemia patients and high TCP1 expression was associated with low complete response rate along with poor overall survival.

Popular